Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 agonist, which Lilly renamed mazisotine, recently came through a phase 2 ...

Eli Lilly and Co. officially opened its new Lilly Seaport Innovation Center on Tuesday. Gary Higgins / Boston Business Journal 1 of 11 By Hannah Green – Reporter, Boston Business Journal Aug 13 ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH By Nick Paul Taylor Feb 10, 2025 9:40am Eli Lilly MASH radiopharmaceuticals Licensing deals ...

Lilly will build a $4.5B R&D and manufacturing facility. dubbed the Lilly Medicine Foundry, at the huge complex it is constructing in Lebanon, Indiana.

Eli Lilly officials and Gov. Mike Braun break ground on the LEAP District's Lilly Medicine Foundry, a $4.5 billion project creating 400 jobs.

Image source: Getty Images. Comparing Eli Lilly and Viking Therapeutics Every market leader started somewhere, and Eli Lilly's history of innovation spans 149 years since its founding in 1876.

Shares of Eli Lilly (LLY 0.55%) and Novo Nordisk (NVO 2.80%) have been climbing steadily over the past 30 days, with the former gaining 19% and the latter rising by 12%.

Unlike many of its big pharma peers, Eli Lilly (LLY -1.04%) is a growth stock that's likely to maintain a faster-than-average pace of expansion over the next few years. Between its massive ...